Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

onically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant changes in hematologic or other laboratory parameters.

Part 3 is a multi-center, observ
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
(Date:11/24/2014)... 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ... President and CEO of Inovio Pharmaceuticals, will be joined by ... the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, at ... listing on the Nasdaq Global Select Market.  ... "We are honored to ring the Nasdaq Opening Bell on ...
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3
... Oct. 30 Novo Nordisk Inc. announced the re-launch ... campaign through a rebranded Web site and a ... many daily challenges, and Novo Nordisk is committed to ... lifetime of possibilities. , These new online resources were ...
... 30 NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... today announced it will hold a conference call on Friday, ... to report results for its third quarter 2009. , ... and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer. ...
Cached Medicine Technology:Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results 2NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results 3
(Date:11/23/2014)... (PRWEB) November 24, 2014 For the ... and retailer, has launched a great promotion for many ... ). Customers can get the best choice with amazing ... shopping at Tidebuy.com. , It is easy to ... now. Besides that, this selection is also famous for ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank company, ... 8 year warranty on its selected hot water tanks. As ... to the impending winter season, it was important for Pro ... that the company provides. As a result, Pro Ace will ... Bradford hot water tanks. , “Every installer who works ...
(Date:11/23/2014)... 2014 (HealthDay News) -- The holidays can be a ... overload can trigger major meltdowns, an expert says. ... of circumstances, but when you have children with special ... occupational therapy professor at University of the Sciences in ... best to let your hosts or visitors know what ...
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... November 23, 2014 AngelWeddingDress.com ... a new selection of beach wedding dresses. “If you ... prices, visit AngelWeddingDress.com as soon as possible. Here you ... The sales manager says. , Holding a big marriage ... And choosing a beautiful beach wedding dress is uppermost ...
Breaking Medicine News(10 mins):Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... Reveal Deficiencies in Care for Individuals across the Country , ... Members who recently sought expert medical consultations from Best ... course of treatment, according to data released today. , ... clinical reviews of cases of Best Doctors members. Best Doctors ...
... Need to Reduce Disparities in Meningococcal Vaccination; Increase Educational ... Md., Dec. 2 The National Foundation ... Outreach. Protect.) Meningitis! coalition, composed of many ... issued a Call to Action to improve adolescent meningococcal ...
... workers, people affected by jet leg , , TUESDAY, Dec. 2 ... insomnia caused by jet lag or night shifts, according to ... II study included 39 people randomly assigned to receive either ... tasimelteon, or a placebo. They were monitored for seven nights ...
... a prototype blood scanner that can find cancer markers ... potentially allowing for earlier treatment and dramatically improved chances ... chips can find cancer-associated proteins in a blood serum ... greater sensitivity than existing commercial devices. In fact, the ...
... new naming structure, Kessler Foundation continues to improve the ... , WEST ORANGE, N.J.Dec. 2 ... disabilities, Henry H. Kessler Foundation, announced today the organization,s ... changing the names of its two main divisions to ...
... , , NEW YORK, Dec. ... JNPC; "Juniper") Sorpresa! , America,s fastest-growing Spanish-language ... Juega Como un MLS Pro , the climax of the ... 7th at 7 PM EST. , , ...
Cached Medicine News:Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:Stanford blood scanner detects even faint indicators of cancer 2Health News:Stanford blood scanner detects even faint indicators of cancer 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Sorpresa! Premieres Juega Como un MLS Pro 2
... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Fluorometholone ophthalmic suspension USP, 0.1% is a topical anti-inflammatory agent for ophthalmic use....
... tool that allows to see the fundus ... stimulated. Besides it also includes the refractive ... between the pupil picture and the fundus ... is especially suited for animal research and ...
Medicine Products: